Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.23.3
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:        
Research and development $ (14,852) $ (4,353) $ (30,248) $ (11,777)
General and administrative (1,833) (2,681) (5,789) (10,680)
Total operating expenses (16,685) (7,034) (36,037) (22,457)
Operating loss (16,685) (7,034) (36,037) (22,457)
Interest expense, net (300) (636) (1,023) (2,441)
Adjustments to fair value of derivatives 13,199 (4,834) 11,361 2,498
Cancellation of share options   17,350   17,350
Other income, net 70 175 161 606
Total other income / (expense) 12,969 (22,645) 10,499 (16,687)
Loss before income taxes (3,716) (29,679) (25,538) (39,144)
Income tax (expense) / benefit (161) 570 (471) (200)
Net loss $ (3,877) $ (29,109) $ (26,009) $ (39,344)
Net loss per share - basic $ (0.3) $ (2.38) $ (2.02) $ (3.22)
Net loss per share - diluted $ (0.3) $ (2.38) $ (2.02) $ (3.22)
Weighted average ordinary shares outstanding - basic 13,039,437 12,233,374 12,888,869 12,217,188
Weighted average ordinary shares outstanding-diluted 13,039,437 12,233,374 12,888,869 12,217,188
Statements of Comprehensive Loss [Abstract]        
Net loss $ (3,877) $ (29,109) $ (26,009) $ (39,344)
Unrealized gain on marketable securities 29   353  
Comprehensive loss $ (3,848) $ (29,109) $ (25,656) $ (39,344)